We report two pediatric patients with rifampin-induced hemolysis following treatment with low daily dose rifampin for methicillin-resistant Staphylococcus aureus (MRSA). With the increased use of rifampin to treat MRSA, physicians should be aware that patients receiving rifampin therapy are at risk for hemolysis, even at low daily doses.
|Original language||English (US)|
|Number of pages||3|
|Journal||Pediatric Blood and Cancer|
|State||Published - Dec 2008|
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health